We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App

Gene Panel Predicts Likelihood of Favorable Response by Multiple Myeloma Patients to Selinexor Treatment

By LabMedica International staff writers
Posted on 16 Jun 2022
Print article
Image: Histopathological image of multiple myeloma in a bone marrow aspirate (Photo courtesy of Wikimedia Commons)
Image: Histopathological image of multiple myeloma in a bone marrow aspirate (Photo courtesy of Wikimedia Commons)

A novel three-gene expression signature has been identified that can be used to predict the response of multiple myeloma (MM) patients to the chemotherapeutic drug selinexor.

Selinexor is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus preventing the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis.

The most common side effects of selinexor treatment include nausea, vomiting, decreased appetite, weight loss, diarrhea, tiredness, thrombocytopenia (low blood-platelet counts), anemia, low levels of white blood cells, and hyponatraemia (low blood sodium levels). Due to these relatively severe side effects, it is important to identify patients who will respond positively and, thereby, potentially expand the use of the drug. However, there currently are no known genomic biomarkers or assays to help select MM patients at higher likelihood of favorable response to selinexor.

Investigators at the Mount Sinai School of Medicine (New York, NY, USA) sought to discover relevant biomarkers by performing RNA sequencing, differential gene expression, and pathway analysis on CD138+ cells from the bone marrow of 100 patients with MM. The three-gene signature (WNT10A, DUSP1, and ETV7) identified in the first part of the study was validated in 64 patients from the Selinexor Treatment of Refractory Myeloma (STORM) cohort of triple-class refractory MM and additionally in an external cohort of 35 patients treated in a real-world setting outside of clinical trials.

Results revealed that the three-gene signature correlated with both depth and duration of response to selinexor in MM, and that it also was validated in a different tumor type using a cohort of pre-treatment tumors from patients with recurrent glioblastoma.

Senior author Dr. Samir Parekh, professor of medicine, hematology, and medical oncology at the Mount Sinai School of Medicine, said, “Our findings provide the basis for improving patient selection for targeted agents using a small panel of genes to guide precise application of these drugs in real world scenarios, including relapse following CAR-T, an increasingly important clinical challenge in myeloma.”

The study was published in the June 15, 2022, online edition of the journal JCO Precision Oncology.

Related Links:
Mount Sinai School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.